Search RLAY
Relay Therapeutics, Inc.
Nasdaq · CIK 1812364
Last close18.96
Daily change+0.47 (2.54%)
10 Years gain-45.91%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RLAY · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
51.3Momentum
0.0Acceleration
38.0Confidence
83.0Annual Revenue6
Quarterly Revenue17
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality16.4 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
ROIC expansionROIC improved by 8.9997 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 6006.1643 percentage points.
Key Metrics
Revenue Growth TTM-77.23%OK
Revenue CAGR 3Y123.2%OK
Gross Margin100%OK
Operating Margin-8,111.55%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-34.64%OK
Incremental Operating Margin 3Y3,949.8%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $15.36M | $15.36M | -$302.74M | -$235.46M | -$235.87M | 100% | -1,971.59% | -1,536.08% | -42.09% | n/a |
| 2025 FY Dec 31, 2024 | $10.01M | $10.01M | -$372.47M | -$249.11M | -$251.13M | 100% | -3,722.07% | -2,509.49% | -46.64% | n/a |
| 2025 FY Dec 31, 2023 | $25.55M | $25.55M | -$373.00M | -$300.32M | -$304.44M | 100% | -1,460.11% | -1,191.74% | -41.9% | n/a |
| 2024 FY Dec 31, 2022 | $1.38M | $1.38M | -$299.28M | -$229.49M | -$238.55M | 100% | -21,670.89% | -17,273.86% | -33.39% | n/a |
| 2023 FY Dec 31, 2021 | $3.03M | $3.03M | -$364.70M | -$74.41M | -$77.88M | 100% | -12,040.21% | -2,571.05% | -61.74% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.03M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-338056, 0001193125-25-269601 |
| Revenue Growth TTM | -77.23% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-338056, 0001193125-25-269601 |
| Revenue CAGR 3Y | 123.2% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076739 |
| Revenue CAGR 5Y | -28.58% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076739 |
| Gross Profit CAGR 3Y | 123.2% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076739 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-338056, 0001193125-25-269601 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-338056, 0001193125-25-269601 |
| Operating Margin | -8,111.55% | Operating Income / Revenue | OK | 0001193125-26-338056, 0001193125-25-269601 |
| ROIC | -34.64% | NOPAT / Average Invested Capital | OK | 0001193125-26-338056, 0001193125-25-269601 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-338056 |
| Current Ratio | 18.27x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-076739 |